Kiniksa Pharmaceuticals saw its IBD SmartSelect Composite Rating jump to 97 Wednesday, up from 83 the day before.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The new score means the company is now outperforming 97% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
Kiniksa Pharmaceuticals broke out earlier, but has fallen back below the prior 30.69 entry from a flat base. In the case where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout. If that happens, it's best to wait for a new base to form.
The stock earns an 80 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
In Q2, the company reported 0% earnings-per-share growth. Sales growth came in at 44%, down from 73% in the prior quarter.
Kiniksa Pharmaceuticals holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
